Endoplasmic reticulum (ER) stress significantly drives the progression of liver cancer and shapes a hostile tumor microenvironment. Researchers recently investigated how PERK inhibition in HCC can mitigate these effects using the selective inhibitor AMG-PERK. They found that blocking the PERK signaling pathway reduces tumor burden and slows cell proliferation. Moreover, this intervention effectively shuts down the communication between tumor cells and the surrounding stroma. Therefore, targeting this pathway provides a dual benefit by attacking both malignant hepatocytes and their supportive environment.

Mechanisms of PERK Inhibition in HCC and Stromal Blocking

The study reveals that ER stress enhances tumor-stromal crosstalk through the secretion of glycoprotein GP73. Specifically, GP73 activates hepatic stellate cells via GRP78-dependent signaling pathways. This activation promotes fibrosis and inflammation, which further fuel cancer growth. However, pharmacological PERK inhibition in HCC or the use of GRP78-targeting antibodies successfully blocks this fibrogenic response. Consequently, the researchers observed a marked reduction in inflammatory signaling and stromal activation within the tumor microenvironment.

Furthermore, transcriptomic profiling showed that PERK signaling drives several oncogenic programs, including MYC signaling and epithelial-to-mesenchymal transition. In contrast, inhibiting PERK reversed these aggressive features in both in vivo models and patient-derived organoids. Notably, single-cell RNA sequencing confirmed that PERK and GP73 are upregulated in malignant cells. Thus, these findings establish PERK as a critical driver of malignancy and a promising therapeutic target for early-stage hepatocarcinogenesis.

Frequently Asked Questions

How does PERK inhibition affect the tumor microenvironment?

PERK inhibition reduces the activation of hepatic stellate cells and decreases fibrosis. By blocking the secretion of GP73, it disrupts the communication between tumor cells and the surrounding stroma, thereby limiting the pro-tumorigenic environment.

What is the role of the GP73-GRP78 pathway in HCC?

GP73 is a glycoprotein secreted by stressed hepatocytes that binds to GRP78 on hepatic stellate cells. This interaction triggers stellate cell activation, leading to increased fibrosis and inflammation that support tumor progression.

Can PERK inhibition be used in early-stage liver cancer?

Yes, research indicates that PERK inhibition is particularly effective during early carcinogenesis. It restrains tumor development, impairs cell viability, and affects oncogenic programs like MYC signaling before the disease reaches advanced stages.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Khaled J et al. Inhibition of PERK signaling suppresses tumor progression and blocks GP73-GRP78-dependent stromal activation in hepatocellular carcinoma. Neoplasia. 2026 Jun 16. doi: undefined. PMID: 42302326.

Bobrovnikova-Marjon E et al. PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Cancer Res. 2010;70(11):4323-4333.

Atkins C et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013;73(6):1993-2002.